Sangamo Biosciences Stock Earnings Reports

Sangamo reported progress across its development programs and regulatory interactions in Q1 2026 while facing financial and listing challenges. The company is mid-way through a rolling BLA submission for ST-920 (isaralgagene civaparvovec) for Fabry disease, with two BLA modules submitted and CMC work ongoing; the FDA affirmed that mean annualized eGFR slope at 52 weeks across all dosed patients can support accelerated approval and confirmed a second confirmatory study is not required, with 104-week data available for traditional approval. Sangamo is pursuing additional capital and strategic options to strengthen its financial position after receiving a NASDAQ delisting determination and moving to the OTCQB Venture Market; they plan to appeal the NASDAQ decision. Neurology programs advanced: six sites activated for the Phase I/II STAND study of ST-503 (epigenetic regulator for intractable pain) and ongoing CTA-enabling activities and GLP toxicology analysis for ST-506 (prion disease). Preclinical and platform data were presented at ASGCT and WORLD; the company highlighted progress on its MINT integrase technology and durable clinical signals for ST-920 (including patients with >5 years follow-up and multiple patients off ERT). Management emphasized continued business development discussions for Fabry commercialization and the need to secure additional funding to complete regulatory submissions and operations.